List of Excipients in Branded Drug DARTISLA ODT

DARTISLA ODT Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

DARTISLA ODT is a glycopyrrolate orally disintegrating tablet developed for adult adjunctive treatment of peptic ulcer disease. Its commercial differentiation depends less on a new active ingredient than on dosage-form convenience, rapid tablet dispersion, dose titration, and patient handling. The formulation uses a conventional ODT excipient platform centered on a water-soluble bulking agent, a disintegrant, a binder, flow-control materials, lubricant, sweetener, and flavoring.[1]

What is DARTISLA ODT and who markets it?

DARTISLA ODT contains glycopyrrolate, an anticholinergic drug. The product is supplied in four strengths:

Product	Glycopyrrolate strength	Dosage form	FDA pathway
DARTISLA ODT	1.7 mg	Orally disintegrating tablet	NDA 215830
DARTISLA ODT	2.3 mg	Orally disintegrating tablet	NDA 215830
DARTISLA ODT	3.1 mg	Orally disintegrating tablet	NDA 215830
DARTISLA ODT	4.4 mg	Orally disintegrating tablet	NDA 215830

Nivagen Pharmaceuticals is identified as the applicant and manufacturer of record in FDA product information. The approved indication is adjunctive treatment of peptic ulcer disease in adults. The product is not approved for the treatment of sialorrhea associated with neurologic disorders, despite glycopyrrolate’s use in that setting through other formulations and prescribing practices.[1,2]

The dosage form is intended to dissolve on the tongue without water. Patients are instructed not to push the tablet through the blister, to place it on the tongue, and to allow it to disintegrate before swallowing.[1]

What excipients are used in DARTISLA ODT?

The DARTISLA ODT inactive-ingredient system includes the following excipient functions:

Excipient or excipient class	Likely formulation function	Commercial relevance
Mannitol	Water-soluble diluent and mouthfeel modifier	Supports a cooling, non-gritty ODT texture
Microcrystalline cellulose	Dry binder and structural excipient	Improves tablet integrity during manufacture and packaging
Crospovidone	Superdisintegrant	Promotes rapid tablet breakup and dispersion
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Reduces ejection force and tooling adhesion
Sucralose	High-intensity sweetener	Masks glycopyrrolate bitterness
Flavoring materials	Taste and sensory masking	Supports patient acceptability

The FDA labeling identifies the inactive ingredients but does not disclose their quantitative concentrations, particle-size specifications, grade selections, or manufacturing sequence.[1] Those parameters are likely controlled in the confidential chemistry, manufacturing, and controls section of NDA 215830.

Why mannitol is commercially important

Mannitol is widely used in ODTs because it provides a pleasant mouthfeel, high water solubility, and a cooling sensation during dissolution. Compared with higher levels of microcrystalline cellulose, mannitol can reduce the chalky or fibrous texture that is particularly noticeable in tablets administered directly on the tongue.

For DARTISLA ODT, mannitol likely performs more than a simple dilution function. It contributes to:

• tablet mass and dose uniformity across the four strengths;
• rapid wetting and dissolution;
• sensory acceptability;
• reduced reliance on water during administration;
• a platform suitable for direct compression or low-moisture processing.

Mannitol grade is a potential supplier and formulation-control issue. Spray-dried and granulated grades can differ in compactability, flow, friability, and disintegration. A switch between grades may require comparative dissolution, hardness, friability, stability, and sensory testing.

Why crospovidone is central to the ODT profile

Crospovidone provides rapid liquid uptake and tablet breakup without forming a viscous gel. That makes it suitable for an ODT where the target is rapid dispersion rather than prolonged tablet integrity.

The formulation balance is sensitive. Too little crospovidone can increase disintegration time and leave a residual tablet core. Too much can reduce compactability, increase friability, or create a rough mouthfeel. The critical manufacturing variables are likely compression force, granule or powder moisture, lubricant level, and crospovidone particle-size distribution.

Taste masking is a core value driver

Glycopyrrolate is an anticholinergic compound and an ODT places the drug in direct contact with taste receptors. Sucralose and flavoring therefore have a functional commercial role. The product does not appear to rely on a complex polymeric taste-masking coating or multiparticulate barrier based on the public inactive-ingredient listing.

That creates a potential opportunity for improved products using:

• ion-exchange resin complexes;
• lipid or polymer taste-masking coatings;
• cyclodextrin complexes;
• microencapsulated glycopyrrolate;
• pH-modified flavor systems;
• lower-residue sweetener systems;
• pediatric or geriatric flavor profiles.

A competing product would need to show that enhanced taste masking does not delay glycopyrrolate release, alter exposure, reduce dose uniformity, or change the product’s comparative performance under the applicable FDA pathway.

What excipient strategies could improve DARTISLA ODT?

The strongest formulation opportunities are in sensory performance, moisture control, disintegration, and packaging.

Faster disintegration without excessive friability

A competing ODT could optimize the balance among mannitol, microcrystalline cellulose, crospovidone, and compression force. A more robust platform may use:

• co-processed mannitol-cellulose excipients;
• dual disintegrants with different wicking mechanisms;
• lower lubricant concentration;
• engineered porous particles;
• roller-compacted or directly compressed blends;
• tablet weights that reduce mouth residence time.

Any improvement must preserve mechanical strength during blister removal. ODTs are vulnerable to edge chipping, capping, and breakage, particularly when the tablet is removed from a peelable foil package.

Better moisture protection

Crospovidone, mannitol, flavoring agents, and tablets with high porosity can be sensitive to humidity. Moisture uptake may change hardness, disintegration, assay, impurity formation, and packaging performance.

Commercially relevant packaging options include:

• high-barrier aluminum-aluminum blisters;
• cold-form foil;
• desiccant-containing bottles;
• unit-dose pouches;
• humidity-controlled secondary packaging.

A formulation that tolerates less expensive packaging could reduce cost of goods. Conversely, a formulation requiring premium foil may raise packaging costs but reduce stability risk and improve shelf-life.

Improved taste and reduced mouth residue

The public excipient profile suggests a relatively simple taste-masking approach. A differentiated product could target:

• less bitterness during the first seconds of dissolution;
• reduced sweetness aftertaste;
• reduced powdery residue;
• lower flavor intensity;
• more consistent sensory performance across strengths.

For commercial adoption, taste claims should be supported by controlled sensory studies. FDA does not treat a favorable taste profile as a substitute for pharmaceutical equivalence, but taste can affect adherence, refill persistence, and caregiver acceptance.

What commercial opportunities exist for DARTISLA ODT?

Adherence and administration convenience

The principal opportunity is administration without water. This may help patients who have difficulty swallowing conventional tablets, patients with limited access to fluids, and patients who need discreet administration.

The opportunity is narrower than the broad ODT market because the approved indication is peptic ulcer disease, a mature therapeutic area with substantial generic treatment alternatives. Glycopyrrolate’s anticholinergic adverse effects also constrain demand. Common risks include dry mouth, constipation, urinary retention, blurred vision, tachycardia, and heat intolerance.[1]

The product’s convenience is therefore most valuable in selected patients rather than as a universal replacement for standard tablets.

Dose-strength and titration economics

The four strengths support titration without tablet splitting. This may create a commercial advantage in prescribing and dispensing, particularly where clinicians want to adjust the dose while avoiding manipulation of an ODT.

The strength ladder also creates inventory complexity. Manufacturers and wholesalers must manage four SKUs, with separate packaging, stability data, artwork, serialization, and forecasting. The 1.7 mg and 4.4 mg strengths may have lower volume than intermediate strengths, creating the risk of uneven channel inventory.

Institutional and specialty-pharmacy channels

The product may be positioned through:

• gastroenterology practices;
• specialty pharmacies;
• long-term-care facilities;
• home-health settings;
• patients with swallowing difficulty;
• prescribers seeking a non-liquid glycopyrrolate option.

Hospital formulary adoption is likely to be limited unless the ODT provides a clear operational benefit over tablets, oral solutions, or alternative anticholinergic products.

Line extensions

Potential line extensions include:

1. A lower-strength ODT for finer titration.
2. A liquid or oral granule formulation for patients unable to handle a tablet.
3. A more strongly taste-masked formulation.
4. A lower-cost generic or authorized-generic version.
5. A formulation targeted to institutional medication carts and unit-dose dispensing.
6. A product with improved moisture robustness and longer in-use stability.

A pediatric formulation would require separate clinical and regulatory analysis and should not be assumed to follow automatically from the adult product.

What generic entry risks exist for DARTISLA ODT?

DARTISLA ODT is an NDA product rather than a conventional abbreviated new drug application product. A competing manufacturer could pursue an ANDA if the product is listed as a reference listed drug and the proposed product meets FDA requirements for pharmaceutical equivalence and bioequivalence. The relevant challenges would include:

• matching each strength;
• demonstrating equivalent dosage form performance;
• matching or appropriately controlling inactive ingredients;
• demonstrating rapid disintegration;
• addressing flavor and sensory differences;
• establishing stability in the proposed packaging;
• resolving any listed patents or regulatory exclusivity.

The ODT dosage form raises technical issues that are less prominent for standard glycopyrrolate tablets. A generic may need to demonstrate that disintegration and dissolution remain comparable despite differences in excipient grade, tablet hardness, flavoring, and packaging.

What is the Orange Book status and patent position?

FDA’s Orange Book is the controlling public source for listed patents, regulatory exclusivity, reference listed drug status, and therapeutic-equivalence information.[3] The public product information identifies DARTISLA ODT as NDA 215830. The commercial risk assessment should distinguish between:

• patents specifically listed against DARTISLA ODT;
• patents covering glycopyrrolate generally;
• formulation or ODT patents;
• method-of-use patents;
• trade-secret manufacturing controls;
• regulatory exclusivity that may expire independently of patents.

A patent covering a particular excipient ratio, taste-masking system, compression process, or moisture-barrier package could be more relevant to DARTISLA ODT than a broad glycopyrrolate composition claim. Public labeling does not disclose the quantitative formulation, so the commercial importance of formulation patents cannot be inferred solely from the inactive-ingredient list.[1,3]

No biosimilar pathway applies. Glycopyrrolate is a small-molecule active ingredient, and a follow-on product would generally proceed through the ANDA or, depending on the proposed changes and regulatory posture, a 505(b)(2) pathway rather than the Biologics Price Competition and Innovation Act pathway.[4]

Paragraph IV and litigation exposure

A Paragraph IV filing would require a generic applicant to certify that relevant listed patents are invalid, unenforceable, or not infringed. Litigation risk would depend on the patents listed for NDA 215830 and the scope of their claims.

The most consequential claim categories would be:

• ODT compositions containing glycopyrrolate;
• excipient ratio claims;
• taste-masking systems;
• rapid-disintegration specifications;
• packaging and moisture-control systems;
• methods of treating peptic ulcer disease with the ODT;
• manufacturing processes that control blend uniformity or content uniformity.

No litigation or settlement outcome should be treated as established without a confirmed case number, court docket, patent number, and settlement record.

How does DARTISLA ODT compare with conventional glycopyrrolate products?

Attribute	DARTISLA ODT	Conventional glycopyrrolate tablet	Glycopyrrolate oral solution
Water required	No	Usually yes	No
Dose manipulation	Four marketed strengths	May require tablet splitting or alternate strength	Flexible volume dosing
Taste exposure	High because tablet dissolves in mouth	Lower	High
Packaging sensitivity	Potentially high	Generally lower	Primarily bottle and liquid stability issues
Manufacturing complexity	ODT compression and moisture control	Conventional tablet manufacture	Liquid filling and preservative or microbial controls
Generic substitution barriers	Dosage-form and performance matching	More established	Formulation and liquid equivalence issues
Main commercial advantage	Convenience and swallowability	Cost and familiarity	Flexible administration

DARTISLA ODT’s commercial proposition is strongest where water-free administration and avoidance of tablet swallowing have measurable value. Its proposition is weaker where price, standard tablet familiarity, or flexible liquid dosing dominates prescribing decisions.

What is the overall patent and commercial strength?

The product has moderate formulation differentiation but a limited active-ingredient moat. Glycopyrrolate is an established small molecule, and the principal defensibility is likely to arise from dosage-form execution, manufacturing controls, brand recognition, regulatory timing, and any unexpired formulation or method patents.

Factor	Assessment
Active-ingredient exclusivity	Limited; glycopyrrolate is established
Dosage-form differentiation	Moderate
Excipient complexity	Low to moderate based on public labeling
Taste-masking differentiation	Potentially meaningful
Manufacturing barrier	Moderate for robust ODT production
Generic substitution risk	Meaningful after applicable exclusivity and patent barriers
Biosimilar risk	None
Pricing power	Likely limited by mature therapeutic category
Best commercial segment	Patients needing water-free or easier administration

Key Takeaways

• DARTISLA ODT uses a conventional ODT excipient architecture built around mannitol, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, sucralose, and flavoring.
• The principal formulation value lies in mouthfeel, rapid dispersion, tablet integrity, taste masking, and moisture control.
• Four dosage strengths support titration but increase SKU and inventory complexity.
• Glycopyrrolate’s established status limits active-ingredient exclusivity and increases long-term generic risk.
• The strongest follow-on opportunities are improved taste masking, lower mouth residue, better humidity tolerance, lower-cost packaging, and optimized disintegration.
• No biosimilar pathway applies.
• Orange Book patents, regulatory exclusivity, Paragraph IV activity, and settlement exposure must be assessed against the current FDA listing for NDA 215830.
• The commercial opportunity is targeted rather than broad: patients who value water-free dosing or have difficulty swallowing conventional tablets.

FAQs

Can DARTISLA ODT be reformulated with different excipients?

Yes. A competing product could use different excipients if it meets the applicable FDA requirements for pharmaceutical equivalence, bioequivalence, stability, dosage-form performance, and safety.

Does DARTISLA ODT have a proprietary excipient system?

The public label identifies the inactive ingredients but does not disclose their quantitative ratios or manufacturing parameters. Proprietary protection, if any, would depend on confidential CMC information and issued patent claims.

Is mannitol essential to an equivalent DARTISLA ODT product?

No. Mannitol is a common ODT excipient, but an equivalent product could use another suitable diluent if the product meets performance and regulatory requirements.

Could a generic use a different flavor from DARTISLA ODT?

Potentially. Flavor differences do not automatically prevent approval, but the applicant must address pharmaceutical equivalence, formulation safety, product performance, and any relevant regulatory requirements.

Is DARTISLA ODT attractive for licensing?

The strongest licensing case would involve a platform that improves taste masking, humidity stability, manufacturing yield, or low-cost ODT production. Licensing value would depend on enforceable IP, demonstrated equivalence or clinical performance, market access, and the status of patents and exclusivity for NDA 215830.

References

1. Nivagen Pharmaceuticals, Inc. (n.d.). DARTISLA ODT (glycopyrrolate) orally disintegrating tablets prescribing information. U.S. Food and Drug Administration labeling database. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA): Generics. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-andacrlf